Shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $8.00 for the company and are predicting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also assigned Pieris Pharmaceuticals an industry rank of 86 out of 265 based on the ratings given to related companies.
Separately, Roth Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Pieris Pharmaceuticals in a report on Friday, August 5th.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.69 on Tuesday. The stock’s market capitalization is $72.77 million. Pieris Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $3.08. The company’s 50 day moving average price is $1.63 and its 200 day moving average price is $1.79.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, August 10th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The business earned $1.07 million during the quarter. On average, equities research analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current year.
Large investors have recently modified their holdings of the company. BlackRock Fund Advisors purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter valued at $113,000. Frontier Wealth Management LLC bought a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $137,000. Sabby Management LLC raised its position in Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock valued at $333,000 after buying an additional 99,792 shares during the last quarter. BVF Inc. IL bought a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $389,000. Finally, Lombard Odier Asset Management USA Corp raised its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock valued at $5,099,000 after buying an additional 533,965 shares during the last quarter. Institutional investors and hedge funds own 45.79% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.